Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$47.98 - $54.4 $34,449 - $39,059
-718 Reduced 13.79%
4,490 $243,000
Q4 2023

Feb 14, 2024

BUY
$48.48 - $57.85 $4,023 - $4,801
83 Added 1.62%
5,208 $267,000
Q3 2023

Nov 14, 2023

BUY
$57.89 - $64.73 $21,998 - $24,597
380 Added 8.01%
5,125 $297,000
Q2 2023

Aug 14, 2023

SELL
$63.71 - $70.74 $3,695 - $4,102
-58 Reduced 1.21%
4,745 $303,000
Q1 2023

May 12, 2023

SELL
$65.71 - $74.53 $657 - $745
-10 Reduced 0.21%
4,803 $332,000
Q4 2022

Feb 14, 2023

SELL
$68.48 - $81.09 $4,040 - $4,784
-59 Reduced 1.21%
4,813 $346,000
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $5 - $3,227
42 Added 0.87%
4,872 $340,000
Q2 2022

Aug 15, 2022

BUY
$72.62 - $79.98 $14,015 - $15,436
193 Added 4.16%
4,830 $372,000
Q1 2022

May 16, 2022

SELL
$61.48 - $73.72 $6,270 - $7,519
-102 Reduced 2.15%
4,637 $351,000
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $804 - $937
15 Added 0.32%
4,739 $295,000
Q2 2021

Aug 16, 2021

SELL
$61.91 - $67.42 $14,858 - $16,180
-240 Reduced 4.83%
4,724 $319,000
Q1 2021

May 17, 2021

SELL
$59.34 - $66.74 $86,933 - $97,774
-1,465 Reduced 22.79%
4,964 $322,000
Q4 2020

Feb 16, 2021

BUY
$57.74 - $65.43 $4,907 - $5,561
85 Added 1.34%
6,429 $399,000
Q3 2020

Nov 16, 2020

SELL
$57.43 - $63.64 $7,523 - $8,336
-131 Reduced 2.02%
6,344 $404,000
Q2 2020

Aug 13, 2020

BUY
$54.82 - $64.09 $75,541 - $88,316
1,378 Added 27.04%
6,475 $412,000
Q1 2020

May 15, 2020

BUY
$46.4 - $67.43 $9,744 - $14,160
210 Added 4.3%
5,097 $284,000
Q4 2019

Feb 11, 2020

SELL
$49.21 - $64.19 $25,490 - $33,250
-518 Reduced 9.58%
4,887 $314,000
Q3 2019

Nov 14, 2019

BUY
$42.77 - $50.71 $231,171 - $274,087
5,405 New
5,405 $274,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Vivaldi Capital Management LP Portfolio

Follow Vivaldi Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vivaldi Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Vivaldi Capital Management LP with notifications on news.